@article{ref1,
title="Determination of burn patient outcome by large-scale quantitative discovery proteomics",
journal="Critical care medicine",
year="2013",
author="Finnerty, Celeste C. and Jeschke, Marc G. and Qian, Wei-Jun and Kaushal, Amit and Xiao, Wenzhong and Liu, Tao and Gritsenko, Marina A. and Moore, Ronald J. and Camp, David G. and Moldawer, Lyle L. and Elson, Constance and Schoenfeld, David and Gamelli, Richard and Gibran, Nicole S. and Klein, Matthew and Arnoldo, Brett D. and Remick, Daniel and Smith, Richard D. and Davis, Ronald and Tompkins, Ronald G. and Herndon, David N.",
volume="41",
number="6",
pages="1421-1434",
abstract="OBJECTIVES:: Emerging proteomics techniques can be used to establish proteomic outcome signatures and to identify candidate biomarkers for survival following traumatic injury. We applied high-resolution liquid chromatography-mass spectrometry and multiplex cytokine analysis to profile the plasma proteome of survivors and nonsurvivors of massive burn injury to determine the proteomic survival signature following a major burn injury. DESIGN:: Proteomic discovery study. SETTING:: Five burn hospitals across the United States. PATIENTS:: Thirty-two burn patients (16 nonsurvivors and 16 survivors), 19-89 years old, were admitted within 96 hours of injury to the participating hospitals with burns covering more than 20% of the total body surface area and required at least one surgical intervention. INTERVENTIONS:: None. MEASUREMENTS AND MAIN RESULTS:: We found differences in circulating levels of 43 proteins involved in the acute-phase response, hepatic signaling, the complement cascade, inflammation, and insulin resistance. Thirty-two of the proteins identified were not previously known to play a role in the response to burn. Interleukin-4, interleukin-8, granulocyte macrophage colony-stimulating factor, monocyte chemotactic protein-1, and β2-microglobulin correlated well with survival and may serve as clinical biomarkers. CONCLUSIONS:: These results demonstrate the utility of these techniques for establishing proteomic survival signatures and for use as a discovery tool to identify candidate biomarkers for survival. This is the first clinical application of a high-throughput, large-scale liquid chromatography-mass spectrometry-based quantitative plasma proteomic approach for biomarker discovery for the prediction of patient outcome following burn, trauma, or critical illness.<p /> <p>Language: en</p>",
language="en",
issn="0090-3493",
doi="10.1097/CCM.0b013e31827c072e",
url="http://dx.doi.org/10.1097/CCM.0b013e31827c072e"
}